Trials / Completed
CompletedNCT02055300
Safety, Tolerability and Pharmacokinetics Study of LY03005
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Luye Pharma Group Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of escalating single oral doses of LY03005 in healthy subjects and to characterize the pharmacokinetics (PK) of escalating single oral doses of LY03005.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY03005 | |
| DRUG | Placebo | |
| OTHER | Meal | |
| DRUG | Pristiq |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2014-02-05
- Last updated
- 2014-11-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02055300. Inclusion in this directory is not an endorsement.